Drug Profile
Research programme: cancer immunotherapeutics - Variagenics
Latest Information Update: 02 Jul 2004
Price :
$50
*
At a glance
- Originator Variagenics
- Class Antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Jul 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 16 Jul 2001 Preclinical trials in Cancer in USA (unspecified route)